Serum Ferritin Levels In Group Research Articles

Study of serum ferritin levels as an inflammatory marker and its relationship with Hba1c in type 2 diabetes mellitus

Type 2 diabetes mellitus is the leading metabolic disorder globally as well as in India, affecting more than 135 million people all over the world.1 Studies have shown a strong association between elevated serum levels of ferritin and type 2 DM.4 Serum ferritin could be an independent determinant of poor metabolic control in the diabetic patient.2 Serum ferritin as an inflammatory marker in type 2 diabetes mellitus is an underutilized but can be a reliable tool to evaluate the metabolic disorder.4 We assessed 180 subjects (120 cases and 60 controls) in the current study. The case group was divided in to 2 groups based on the HbA1c levels as Group B: HbA1C < 6g> 6g/dl (60 cases). The work embodied in the study includes subjects diagnosed of type 2 diabetes mellitus above 40 years of age, attending diabetic OPD in ESIC PGIMSR, of both gender. Group A (control) includes healthy adults above 30 years of age both the sexes. Serum levels Fasting sugar and Ferritin were estimated along with Glycated hemoglobin levels. Mean serum ferritin levels in Group A, Group B and Group C were 112.08 ± 90.1ng/dl, 334.4 ± 39.1ng/mL and 368.9 ± 46.7 ng/ respectively. Serum ferritin levels in Group B and C were significantly higher than Group A (p Keywords: Type 2 diabetes, Serum ferritin, Glycated hemoglobin, Inflammatory marker.

Serum Hepcidin Levels in Diabetic and Non-diabetic Chronic Hepatitis C Patients and Its Relation with Serum Iron Levels

&lt;p&gt;&lt;strong&gt;Background and Objective:&lt;/strong&gt; Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. Research shows that HCV infection leads to a marked reduction of serum&amp;nbsp; hepcidin levels which might be a factor in causing systemic iron overload. The present study was aimed to&amp;nbsp; determine the cause of iron overloadwhich might be due to reduced levels of serum hepcidin in chronic&amp;nbsp; hepatitis C patients.&lt;br /&gt;&lt;strong&gt;Methods:&lt;/strong&gt; This cross-sectional study was conducted in Department of Physiology at University of Health Sciences, Lahorefrom January 2012 to January 2014. A total of 54 male patients of chronic hepatitis C were recruited for this study and divided into two groups, group A (CHC with diabetes) and group B (CHC without diabetes). Both groupswere tested for serum hepcidin, serum iron and serum ferritin levels. ELISA technique was used to measure serum hepcidin. Serum ferritin levels were measured via CODA analyzer. Serum iron levels were measured by colorimetric method. Frequencies and percentages were calculated for serum hepcidin, serum iron and serum ferritin levels in group. The data was analyzed using SPSS (Statistical Package for Social Sciences) version 20.0. Data was considered significant where P-value was &amp;le; 0.05.&lt;br /&gt;&lt;strong&gt;Results:&lt;/strong&gt; Patients in both groups showed less serum hepcidin levelsalong with less serum iron levels in 93% cases of both groups. The patients in group A showed raisedferritin levels in 26% cases and normal ferritin levels in 63% cases. Whereas in group B 04% cases showed raisedferritin levels and 92% patients hadnormal ferritin levels; which could be a marker of ongoing chronic inflammation in CHC patients. Non-significant negative correlation was observed between serum iron and serum hepcidin inCHC population.&lt;br /&gt;&lt;strong&gt;Conclusion:&lt;/strong&gt; Hepatitis C virus and decreased serum iron levels in study population may be the reason of less serum hepcidin levels. Raised/normal ferritin reflects chronic inflammation in patients. Non-significant negative correlation between serum iron and serum hepcidin leads the focus towards increasing the sample size in further studies to see any significant negative correlation between studied parameters.&lt;/p&gt;

The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection

An increase in serum ferritin levels during combined interferon-ribavirin treatment in chronic patients infected with hepatitis C virus (HCV) can occur. A study was conducted to determine whether observing the kinetics of serum ferritin levels during antiviral therapy, may assist in predicting the rate of sustained virological response. The kinetics of serum ferritin levels during antiviral therapy in treatment-naive, adherent patients with chronic HCV who had early virological response were characterized. Thirteen patients achieved sustained virological response (group 1) while eight patients did not (group 2). Pre-treatment serum ferritin levels were higher in group 2 patients. During antiviral therapy, serum ferritin levels increased in both groups. On treatment, the median increase (compared to baseline) and the calculated rate of the increase in serum ferritin levels was higher in group 1 patients (874% vs. 272%, P < 0.05, 63%/week vs. 13%/week, P = 0.024, respectively). Red blood cell lysis did not contribute to the increase in serum ferritin level. Post-treatment (1st month) serum ferritin levels in group 1 patients were lower than in group 2 patients. In addition, the degree of decline in the 1st month serum ferritin levels (from peak levels) in group 1 patients was higher (76% vs. 49%, P = 0.039). Measuring serum ferritin levels during antiviral therapy in HCV patients who had an early virological response may assist in predicting sustained virological response.

Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major

Objective: Variable response to deferiprone has been observed in the management of iron overload in patients with thalassemia major. Our objective was to assess the long-term efficacy of deferiprone in patients with thalassemia major.Methods: We analyzed the serum ferritin levels in fifty-eight patients who were on deferiprone therapy for at least three years. We divided patients into three groups based on the initial serum ferritin level: group 1, <2000 ng/ml; group 2, 2000–4000 ng/ml; group 3, <4000 ng/ml.Results: Repeated measurement analysis showed a fall in serum ferritin level in group 3 after 12 months but again increased after 24 months, whereas other groups showed an increase in serum ferritin after 12 months which was sustained for 3 years. The patients were divided into three groups depending on the comparison of serum ferritin at the beginning and at the end; response group I: patients remained in the same ferritin group (n=30), response group II: patients progressed to more severe group (n=17), response group III: serum ferritin decreased and patient shifted to the lower group of ferritin level (n=11). Comparing various factors which could affect the response to deferiprone among three groups, no factor other than serum ferritin at the beginning of the treatment showed significant effect. However, some patients with a serum ferritin value in the lower range also showed improvement.Conclusion: The major factor determining the response to deferiprone was initial serum ferritin. But some patients responded well even with relatively low initial serum ferritin.

Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection

A high prevalence of diabetes has been reported in patients with hepatitis C virus (HCV) infection. Both diabetes and HCV infection are associated with high serum ferritin levels. Although HCV infection could be the main factor responsible for the high ferritin levels, it is also possible that diabetes rather than HCV infection might be a major contributor to the high ferritin levels observed in patients with HCV infection. The aim of this study was to investigate the contribution of diabetes to the high ferritin levels observed in HCV-infected patients with chronic hepatitis. A total of 634 noncirrhotic individuals were prospectively recruited at a university hospital. According to the HCV antibody status and the presence of diabetes, the subjects were divided into four groups: group A (anti-HCV-positive diabetic patients, n = 53), group B (anti-HCV-negative diabetic patients, n = 242), group C (anti-HCV-positive nondiabetic patients, n = 191), and group D (anti-HCV-negative nondiabetic control subjects, n = 148). Multiple regression analyses were used to explore the variables independently related to ferritin levels. Serum ferritin levels in group A were significantly higher than in the other groups (A > B, P < 0.01; A > C, P < 0.001; A > D, P < 0.001). Ferritin levels were higher in group B than in group D (P = 0.001). However, group C has ferritin values similar to those of group D. In multivariate analyses, diabetes but not HCV infection was independently related to serum ferritin concentrations. Diabetes rather than HCV infection itself is the main factor associated with the increased ferritin levels detected in patients with HCV infection. Therefore, the presence of diabetes should be taken into account when iron metabolism is evaluated in HCV-infected patients.